Summary of Significant Accounting Policies - Segments (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($) segment	Sep. 30, 2024 USD ($)
Segments
Number of reportable segment | segment			1
Revenue	$ 20,689	$ 18,957	$ 59,406	$ 51,651
Cost of revenue (excluding amortization of intangible assets)	6,625	6,004	18,535	16,099
Amortization of intangible assets	95	95	285	285
Gross profit	13,969	12,858	40,586	35,267
Sales and marketing:
Total sales and marketing	15,227	16,472	48,692	50,691
General and Administrative:
Total general and administrative	3,948	3,683	11,910	11,133
Research and Development:
Total research and development	2,348	2,068	7,091	6,784
Gain on sale of product line				7,580
Net loss	(8,603)	(10,372)	(29,790)	(28,633)
Single reportable segment
Segments
Revenue	20,689	18,957	59,406	51,651
Cost of revenue (excluding amortization of intangible assets)	6,625	6,004	18,535	16,099
Amortization of intangible assets	95	95	285	285
Gross profit	13,969	12,858	40,586	35,267
Sales and marketing:
Sales and sales management	10,452	11,854	33,281	34,276
International	1,329	1,200	4,137	3,626
Other sales and marketing	3,446	3,418	11,274	12,789
Total sales and marketing	15,227	16,472	48,692	50,691
General and Administrative:
Finance and Legal	1,842	1,886	5,761	5,747
Other General and administrative	2,106	1,797	6,149	5,386
Total general and administrative	3,948	3,683	11,910	11,133
Research and Development:
Clinical	873	1,026	2,654	3,162
Regulatory and quality	468	347	1,334	1,108
Other research and development	1,007	695	3,103	2,514
Total research and development	2,348	2,068	7,091	6,784
Gain on sale of product line				7,580
Other segment items	(1,049)	(1,007)	(2,683)	(2,872)
Net loss	$ (8,603)	$ (10,372)	$ (29,790)	$ (28,633)